Tonix Pharmaceuticals Holding Corp. 8-K

What Happened

• Tonix Pharmaceuticals (TNXP) filed a Form 8-K on July 13, 2026 announcing it entered into an agreement with a pharmacy benefit manager (PBM) that will provide Medicare Part D coverage for TONMYA. The PBM coverage is effective January 1, 2027 and will cover approximately 9 million Medicare Part D plan beneficiaries. The filing includes a July 13, 2026 press release discussing the matter.

Key Details

• Agreement announced: July 13, 2026 (Form 8-K filing and press release attached).
• PBM coverage effective: January 1, 2027.
• Medicare Part D beneficiaries covered by this PBM agreement: ~9 million.
• Existing Medicaid coverage: TONMYA is currently covered under Medicaid in most states, representing ~73 million Medicaid beneficiaries.
• Combined expected government and commercial coverage on Jan 1, 2027: ~145 million individuals (company estimate).
• Filing includes standard forward-looking statements and cautionary language.

Why It Matters

• Broader insurance coverage can make TONMYA more accessible to patients and may increase prescription uptake and revenue potential if demand follows. Adding Medicare Part D coverage is particularly relevant for older patients who rely on Part D for prescription drug benefits. Investors should note the effective date (Jan 1, 2027) and the company’s estimate of total covered lives (~145 million) as potential drivers for future sales, while remembering the filing contains forward-looking statements and associated risks.